The estimated Net Worth of Francisco Leon is at least $43.8 Million dollars as of 10 February 2023. Mr. Leon owns over 75,985 units of Provention Bio stock worth over $39,942,645 and over the last 5 years he sold PRVB stock worth over $0. In addition, he makes $3,846,460 as Co-Founder and Chief Scientific Officer at Provention Bio.
Francisco has made over 12 trades of the Provention Bio stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 75,985 units of PRVB stock worth $189,963 on 10 February 2023.
The largest trade he's ever made was exercising 187,000 units of Provention Bio stock on 29 December 2022 worth over $467,500. On average, Francisco trades about 15,482 units every 61 days since 2019. As of 10 February 2023 he still owns at least 1,598,985 units of Provention Bio stock.
You can see the complete history of Mr. Leon stock trades at the bottom of the page.
Francisco Leon M.D., Ph.D. serves as Co-Founder, Chief Scientific Officer of the Company. Dr. Leon, co-founder of Provention and its Chief Scientific Officer, joined Provention in October 2017. Dr. Leon brings to the Company a breadth of experience and expertise from his academic and industry careers in the fields of immunology and immune-mediated disease clinical research. Dr. Leon was most recently the Chief Executive Officer and Chief Medical Officer of Celimmune, LLC, a clinical development-stage immunotherapy company dedicated to developing transformational therapies for celiac disease and refractory celiac disease (intestinal lymphoma). Celimmune was acquired by Amgen Inc. in November 2017. Prior to founding Celimmune in 2015, Dr. Leon served as Vice President and Head of Translational Medicine at Johnson & Johnson’s Janssen Pharmaceuticals, where he led early-stage clinical development in immunology. Before joining Janssen in 2010, Dr. Leon served as Chief Medical Officer at Alba Therapeutics; Director of Clinical Development, Inflammation & Respiratory at Medimmune (AstraZeneca); and Director of Clinical Discovery, Immunology & Oncology at Bristol-Myers Squibb. Prior to joining the biopharma industry, Dr. Leon served as a Postdoctoral Fellow at the National Institutes for Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH). In 2011, he became an Associate Professor of Medicine at Jefferson Medical College in Philadelphia, where he continues to contribute to the clinical research efforts of the Department of Gastroenterology. Dr. Leon is a clinical and translational immunologist who received his M.D. and Ph.D. from Autónoma University in Madrid, Spain, and his specialization in Clinical Immunology from Ramon y Cajal Hospital, Madrid, Spain. He is a Fellow of the American Gastroenterology Association. In his 20 years of experience in translational immunology, Dr. Leon has authored or co-authored more than 85 peer-reviewed articles and book chapters, as well as several issu
As the Co-Founder and Chief Scientific Officer of Provention Bio, the total compensation of Francisco Leon at Provention Bio is $3,846,460. There are 2 executives at Provention Bio getting paid more, with Ashleigh Palmer having the highest compensation of $3,959,460.
Francisco Leon is 48, he's been the Co-Founder and Chief Scientific Officer of Provention Bio since 2019. There are 12 older and 3 younger executives at Provention Bio. The oldest executive at Provention Bio, Inc. is Avery Catlin, 72, who is the Independent Director.
Francisco's mailing address filed with the SEC is C/O PROVENTION BIO, INC., 55 BROAD STREET, 2ND FLOOR, RED BANK, NJ, 07701.
Over the last 6 years, insiders at Provention Bio have traded over $81,606,241 worth of Provention Bio stock and bought 165,475 units worth $1,543,065 . The most active insiders traders include Capital (Master), L.P.Sessa..., Nancy Wysenski, and Avery W Catlin. On average, Provention Bio executives and independent directors trade stock every 35 days with the average trade being worth of $3,621,900. The most recent stock trade was executed by Capital (Master), L.P.Sessa... on 14 April 2023, trading 2,190,549 units of PRVB stock currently worth $53,274,152.
Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one diabetes (T1D); PRV-3279, which has completed Phase Ib clinical trial for the treatment of lupus; PRV-101, a coxsackie virus B (CVB) vaccine for the prevention of acute CVB infections and onset of T1D; and PRV-015, which is in phase IIb clinical trial for the treatment of gluten-free diet non-responding celiac disease. The company has a license and collaboration agreement with Amgen Inc. for PRV-015, a novel anti-IL-15 monoclonal antibody being developed for the treatment of gluten-free diet non-responsive celiac disease; and a strategic collaboration with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. to develop and commercialize PRV-3279, a bispecific antibody-based molecule targeting the B cell surface proteins CD32B and CD79B in Greater China. Provention Bio, Inc. was incorporated in 2016 and is headquartered in Red Bank, New Jersey.
Provention Bio executives and other stock owners filed with the SEC include: